Innate Pharma SA
IPHYFDrugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
MIS416
Secondary Progressive Multiple Sclerosis
IPH4102
Lymphoma, T-Cell
IPH6501
Non Hodgkin Lymphoma
IPH2101
Smoldering Multiple Myeloma
Monalizumab
Head and Neck Neoplasms
IPH2102 at 0.1 mg/kg
Acute Myeloid Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MIS416 | Phase 2 | Secondary Progressive Multiple Sclerosis | - | - |
IPH4102 | Phase 2 | Lymphoma, T-Cell | - | - |
IPH6501 | Phase 2 | Non Hodgkin Lymphoma | - | - |
IPH2101 | Phase 2 | Smoldering Multiple Myeloma | - | - |
Monalizumab | Phase 2 | Head and Neck Neoplasms | - | - |
IPH2102 at 0.1 mg/kg | Phase 2 | Acute Myeloid Leukemia | - | - |
Frequently asked questions
What is in Innate Pharma SA's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Innate Pharma SA's (IPHYF) pipeline across Phase 2. Its lead program is MIS416 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Innate Pharma SA's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Innate Pharma SA (IPHYF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IPHYF biotech catalysts?→
Add IPHYF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Innate Pharma SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.